Restrictive chronic lung allograft dysfunction: Where are we now?

Journal of Heart and Lung Transplantation

Volumn 34, Issue 5, 2015, Pages 625-630

  Verleden, Stijn E ^a   Ruttens, David ^a   Vandermeulen, Elly ^a   Bellon, Hannelore ^a   Van Raemdonck, Dirk E ^a   Dupont, Lieven J ^a   Vanaudenaerde, Bart M ^a   Verleden, Geert ^a   Vos, Robin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bronchiolitis obliterans syndrome; Chronic lung allograft dysfunction; Lung transplantation; Restriction; Restrictive allograft syndrome

Indexed keywords

ALEMTUZUMAB; PIRFENIDONE;

ACUTE GRAFT REJECTION; ARTICLE; ARTIFICIAL VENTILATION; BRONCHIOLITIS OBLITERANS; COMPUTER ASSISTED TOMOGRAPHY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT DYSFUNCTION; HEART LUNG TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NONHUMAN; OPEN LUNG BIOPSY; ORGANIZING PNEUMONIA; OXYGEN SUPPLY; PHENOTYPE; PLEURA THICKENING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RESTRICTIVE CHRONIC LUNG ALLOGRAFT DYSFUNCTION; RISK FACTOR; THIN LAYER CHROMATOGRAPHY; TRANSBRONCHIAL BIOPSY; ALLOGRAFT; BELGIUM; CHRONIC DISEASE; INCIDENCE; PRIMARY GRAFT DYSFUNCTION;

ALLOGRAFTS; BELGIUM; BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; HUMANS; INCIDENCE; LUNG TRANSPLANTATION; PRIMARY GRAFT DYSFUNCTION; PROGNOSIS; RISK FACTORS;

EID: 84933178573     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2014.11.007     Document Type: Editorial

References (32)

1. Verleden GM, Raghu G, Meyer KC, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 2014;33:127-33.
2. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984;86:824-9.
3. Yousem SA, Burke CM, Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol 1985;16:911-23.
4. Haverich A, Dawkins KD, Baldwin JC, et al. Long-term cardiac and pulmonary histology in primates following combined heart and lung transplantation. Transplantation 1985;39:356-60.
5. Theodore J, Jamieson SW, Burke CM, et al. Physiologic aspects of human heart-lung transplantation. Pulmonary function status of the post-transplanted lung. Chest 1984;86:349-57.
6. Tazelaar HD, Yousem SA. The pathology of combined heart-lung transplantation: an autopsy study. Hum Pathol 1988;19:1403-16.
7. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310.
8. Burton CM, Iversen M, Carlsen J, et al. Interstitial inflammatory lesions of the pulmonary allograft: a retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008;86:811-9.
9. Martinu T, Howell DN, Davis RD, et al. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest 2006;129:1016-23.
10. Pakhale SS, Hadjiliadis D, Howell DN, et al. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant 2005;24:1260-8.
11. Woodrow JP, Shlobin OA, Barnett SD, et al. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant 2010;29:1159-64.
12. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011;30:735-42.
13. Verleden GM, Vos R, Verleden SE, et al. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 2011;92:703-8.
14. Todd JL, Jain R, Pavlisko EN, et al. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am J Respir Crit Care Med 2014;189:159-66.
15. Verleden SE, Vandermeulen E, Ruttens D, et al. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med 2013;34:352-60.
16. Paraskeva M, McLean C, Ellis S, et al. Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med 2013;187:1360-8.
17. Sato M, Hwang DM, Waddell TK, et al. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant 2013;32:23-30.
18. Verleden SE, de Jong PA, Ruttens D, et al. Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant 2014;33:270-7.
19. Vos R, Verleden SE, Ruttens D, et al. Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant 2013;13:3035-40.
20. Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol 2013;26:350-6.
21. Sato M, Hwang DM, Ohmori-Matsuda K, et al. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. J Heart Lung Transplant 2012;31:354-63.
22. Shino MY, Weigt SS, Li N, et al. CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction. Am J Respir Crit Care Med 2013;188:1117-25.
23. Verleden SE, Ruttens D, Vandermeulen E, et al. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? Transplantation 2013;95:1167-72.
24. Verleden SE, Ruttens D, Vandermeulen E, et al. Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation. Transplantation 2014;97:83-9.
25. Verleden SE, Ruttens D, Vos R, et al. Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction. Transplantation (in press).
26. Saito T, Takahashi H, Kaneda H, et al. Impact of cytokine expression in the pre-implanted donor lung on the development of chronic lung allograft dysfunction subtypes. Am J Transplant 2013;13: 3192-201.
27. Saito T, Liu M, Binnie M, et al. Distinct expression patterns of alveolar "alarmins" in subtypes of chronic lung allograft dysfunction. Am J Transplant 2014;14:1425-32.
28. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
29. Kohno M, Perch M, Andersen E, et al. Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplant Proc 2011;43:1868-70.
30. Greer M, Dierich M, de Wall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant 2013;13:911-8.
31. Verleden SE, Todd J, Sato M, et al. Survival after redo-lung transplantation for CLAD according to phenotype - a multi-center study. ERS Munich 2014.
32. Opelz G, Dohler B, Ruhenstroth A, et al. The collaborative transplant study registry. Transplant Rev (Orlando) 2013;27:43-5.